Table 1.
Patient characteristics and test results.
| Case 1 | Case 2 | |||
|---|---|---|---|---|
| Age | 26 | 49 | ||
| Sex | F | F | ||
| Vaccination | Vaxzevria (AstraZeneca, Sweden) | Spikevax (Moderna Biotech, Spain) | ||
| Onset of symptoms | 2 weeks | 2 weeks | ||
| Ultrasound | Distinct ill-defined hypoechoic areas with decreased blood flow | Distinct ill-defined hypoechoic area with decreased blood flow | ||
| FNAC | Follicular cells, mononuclear lymphocytic cells, granulomatous cells, and multinucleated giant cells | Follicular cells, lymphocytes, macrophages, and multinucleated giant cells | ||
| Laboratory test results | Initial | Follow-up (6 weeks) | Initial | Follow-up (4 weeks) |
| TSH (0.35–4.94 mIU/l) | 1.75 | 0.83 | 0.5 | 0.01 |
| fT3 (1.71–3.71 ng/l) | 3.72 | 2.6 | 3.25 | 3.97 |
| fT4 (7.0–14.8 ng/l) | 9.3 | 9.0 | 9.4 | 13.9 |
| Anti-TPO (<6 IU/ml) | Neg | Neg | Neg | 33 |
| Anti-Tg (<14 IU/ml) | Neg | Neg | Neg | Neg |
| TRAB (<1.75 IU/l) | Neg | Neg | Neg | Neg |
| CRP (<5.0 mg/l) | 29.4 | 1.0 | 21.9 | 22.4 |
| WBC (4.0–11.0 103/μl) | 14.3 | 9.77 | 7.86 | 5.75 |
FNAC, fine-needle aspiration cytology; TSH, thyroid-stimulating hormone; fT3, triiodothyronine; fT4, thyroxine; Anti-TPO, anti-thyroid peroxidase antibodies; Anti-Tg, Anti-thyroglobulin antibodies; TRAB, anti-thyroid stimulating hormone receptor antibodies; CRP, C-reactive protein; WBC, white blood cells.